Hematological Oncology
Published by John Wiley & Sons
ISSN : 0278-0232 eISSN : 1099-1069
Abbreviation : Hematol. Oncol.
Aims & Scope
Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters.
Translational studies applying basic science to clinical issues are particularly welcomed.
Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems.
Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community.
Proposals for review material may be discussed with the Editor-in-Chief.
Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.
View Aims & ScopeMetrics & Ranking
Impact Factor
Year | Value |
---|---|
2025 | 3.9 |
2024 | 3.30 |
SJR (SCImago Journal Rank)
Year | Value |
---|---|
2024 | 1.027 |
Quartile
Year | Value |
---|---|
2024 | Q1 |
h-index
Year | Value |
---|---|
2024 | 57 |
Journal Rank
Year | Value |
---|---|
2024 | 4613 |
Journal Citation Indicator
Year | Value |
---|---|
2024 | 877 |
Impact Factor Trend
Abstracting & Indexing
Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.
Subjects & Keywords
Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Medicine, designed to support cutting-edge academic discovery.
Most Cited Articles
The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.
-
Growth fractions in malignant nonâ€Hodgkin's lymphomas (NHL) as determined<i>in situ</i>with the monoclonal antibody Kiâ€67
Citation: 252
Authors: Johannes, Frederike, Karl, Hilmar, Harald
-
Clinical and prognostic relevance of the Kiel classification of nonâ€Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group
Citation: 165
Authors: G., H., H., E., H. H., U., T., R., E., P., M., H., H., W., C., T., K., A., H., F., W. D., W., A., G. W., H., J., H., K.â€M., I., D., T., A., L., H. W., P. G., H., M., M., H., G., E., R., U., H. J., E.â€W., H., A. C., K.
-
Criteria for the cytologic subclassification of follicular lymphomas: A Proposed alternative method
Citation: 158
Authors: Risa B., Costan W.
-
PRESENCE OF EPSTEINâ€BARR VIRUS DNA IN NASAL LYMPHOMAS OF B AND ‘T’ CELL TYPE
Citation: 144
Authors: F. C. S., G., S. L., K. H., B. P. Y., R., D.
-
Prognostic impact of tumourâ€infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma
Citation: 136
Authors: Sabine, Daniela, Maike, Luitpold, Gerhard, Lawrence S., Gerald
-
Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis
Citation: 131
Authors: P., M., H., T., H. H., K., U., K., W., E., H. J., R., H., W.â€D., K., H., H., W. D., H. J., H., K. H., Th., K., G.